当前位置: 首页 > 详情页

Reversal of multidrug resistance by magnetic chitosan-Fe3O4 nanoparticle-encapsulated MDR1 siRNA in glioblastoma cell line

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China; [2]Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [3]Capital Med Univ, Beijing Neurosurg Inst, 6 Tian Tan Xili, Beijing 100050, Peoples R China
出处:
ISSN:

关键词: Gene therapy Glioma Nanoparticle RNA interference

摘要:
Objective: To investigate the reversal effects of MDR1 gene on multidrug resistance in the glioblastoma cell line BT325 by magnetic chitosan-Fe3O4 nanoparticle-encapsulated MDR1 siRNA. Methods: The shRNA expression vector was constructed and the recombinant plasmids were cloned. Magnetic chitosan-Fe3O4 nanoparticles were prepared and the encapsulation rate was determined. After transfection, the BT325 cells were cultured to assay the transfection efficiency. The changing of MDR1 mRNA level and P-gp protein was evaluated. And the sensitivity to different chemotherapeutic drugs was assessed in BT325-siRNA transfected cell and untransfected cell by IC50 values. Results: The MDR1 RNAi plasmid was successfully designed and preparation. The encapsulation efficiency of the magnetic chitosan-Fe3O4 nanoparticle was 98-99%. The transfection efficiency of the siRNA-nanoparticles in BT325 cells was 70-80%. And the MDR1 mRNA levels were downregulated by reverse transcription (RT)-PCR assay. Furthermore, the results of P-gp protein expression decreased on immunocytochemical assay, Western blot and flow cytometry compared with control group. The IC50 values of DOX and VCR were decreased between the transfected cell and normal BT325 cell. Conclusion: After targeted transfection of the glioblastoma cell line with magnetic chitosan-Fe3O4 nanoparticle-encapsulated MDR1 siRNA, the expression of MDR1 at both the mRNA and protein level decreased, which increased sensitivity to chemotherapy in vitro. It might provide a basis for investigation of the mechanism involved in multidrug resistance in glioma.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学 4 区 神经科学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学 4 区 神经科学
JCR分区:
出版当年[2011]版:
Q3 CLINICAL NEUROLOGY Q4 NEUROSCIENCES
最新[2023]版:
Q3 CLINICAL NEUROLOGY Q4 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China;
通讯作者:
通讯机构: [2]Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [3]Capital Med Univ, Beijing Neurosurg Inst, 6 Tian Tan Xili, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院